One in three Covid-19 deaths may be linked to health insurance gaps
A recent report from Families USA finds that uninsurance was associated with 44% of Covid-19 infections and 32% of deaths in the US. More
Vaccine distribution effort falls behind on equity
Ever since Covid-19 vaccines have been in development, policy experts and activists have been concerned about equity in vaccine distribution. Now, it is clear that in our haste to get "shots in arms," we are leaving behind many people who are most at risk of Covid-19 infection and death. More
The Pfizer-BioNtech vaccine: Good news and what we still don’t know
Ever since the initial press release from Pfizer came out, the medical community has been waiting for more detailed results to better analyze the vaccine's effectiveness and safety. Here's what the briefing document shows. More
When evidence becomes politicized, how do we talk about low-value care?
When we call unproven treatments "cures," we not only put patients at risk of harm, we create a framework in which evidence is no longer valued. Kelsey Chalmers and Judith Garber explore how this perspective could impact the "less is more" movement, and how we need to reframe the issue to build a coalition for change. More
Debunking popular Covid-19 myths
Misinformation about Covid-19 spreads as quickly as the virus, through social media and even from government officials. Let's examine some popular myths about Covid-19 and see if there is any truth to these claims. More
What Trump’s Covid-19 experience reveals about our pandemic response
Did Trump receive the "best care possible"? Or was he overtreated? More
Are Covid-19 resources going to those who need them most?
From drugs to masks to financial assistance, the US government has distributed Covid-19 resources in a way that exacerbates health inequities. How can we make sure that when a vaccine is ready for distribution, that it goes to those who need it most? More
The convalescent plasma roller coaster
The FDA's about-face on emergency approval of convalescent plasma raises questions about the level of evidence we need for Covid-19 treatments, and the role of politics in these decisions. More
Covid-19 puts more pressure on state budgets
State budgets have been squeezed over the past decade due in large part to the rising cost of health care, and Covid-19 is only making it worse. What can we do about this problem? More
Remdesivir report sparks more debate on drug price value
How much should remdesivir cost? This question puts two drug-value organizations at odds. More